CoChat

Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta‐analysis

Open access
Turner, Richard M., Kwok, Chun S., Chen‐Turner, Chen, Maduakor, Chinedu A., Singh, Sonal, Loke, Yoon K. · 2014 · British Journal of Clinical Pharmacology
Cited by 127

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Aims: To determine whether thiazolidinedione use is associated with a risk of bladder cancer. Methods: We searched MEDLINE and EMBASE in J une 2012 (with P ub M ed update to J uly 2013) and conducted meta‐analysis on the overall risks of bladder cancer with pioglitazone or rosiglitazone and the risk with different categories of cumulative dose or duration of drug use. Results: We screened 230 citations and included 18 studies, comprising five randomized controlled trials ( RCT s) and 13 observational studies. Meta‐analysis showed a significantly higher overall risk of bladder cancer with pioglitazone in RCT s [7878 participants; odds ratio ( OR ) 2.51, 95% confidence interval ( CI ) 1.09–5.80] and observational studies (>2.6 million patients; OR for ‘ever’ users vs . non‐users 1.21, 95% CI 1.09–1.35). Subgroup analysis of observational studies by cumulative dose showed the risk of bladder cancer to be greatest with >28.0 g of pioglitazone ( OR 1.64, 95% CI 1.28–2.12). A significantly increased risk was found with both 12–24 months ( OR 1.41, 95% CI 1.16–1.71) and >24 months ( OR 1.51, 95% CI 1.26–1.81) cumulative durations of pioglitazone exposure. No significant risk was seen with rosiglitazone in RCTs ( OR 0.84, 95% CI 0.35–2.04) or ‘ever’ users vs . non‐users in observational studies ( OR 1.03, 95% CI 0.94–1.12); the evidence for any relationship between bladder cancer risk and rosiglitazone cumulative duration is limited and inconsistent. Direct comparison of pioglitazone to rosiglitazone ‘ever’ users yielded an OR of 1.25 (95% CI 0.91–1.72). Conclusions: A modest but clinically significant increase in the risk of bladder cancer with pioglitazone was found, which appears to be related to cumulative dose and duration of exposure. We recommend that prescribers limit pioglitazone use to shorter durations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bcp.12306

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 127

Metadata

Authors
Turner, R. M., Kwok, C. S., Chen‐Turner, C., Maduakor, C. A., Singh, S., & Loke, Y. K.
Venue
British Journal of Clinical Pharmacology
Publisher
Wiley
Published
2014-07-21
Volume
78
Issue
2
Pages
258-273
ISSN
  • 0306-5251 (ISSN-L)
  • 1365-2125
OpenAlex
W1752522506
Cited by
127
References
10
FWCI
1.19
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.